In conclusion, we show that ctDNA testing, with the assays employed in this study, has sufficient accuracy for widespread adoption in routine clinical practice to identify patients with breast cancer who are suitable for licensed targeted therapies, such as PIK3CA-mutant breast cancer, with the transformative potential of efficient and rapid screening for clinical trials. This evidence concerns the gene PIK3CA and breast carcinoma.